Abstract
Despite the availability of various antihyperglycaemic therapies and comprehensive guidelines, glycaemic control in diabetes management has not improved significantly during the last decade in the real-world clinical setting. Treatment inertia arising from a complex interplay among patient-, clinician- and healthcare-system-related factors is the prime reason for this suboptimal glycaemic control. Also, the key factor leading to inadequate glycaemic levels remains limited communication between healthcare professionals (HCPs) and people with type 2 diabetes (PwT2D). Early insulin administration has several advantages including reduced glucotoxicity, high efficacy and preserved β-cell mass/function, leading to lowering the risk of diabetes complications. The current publication is based on consensus of experts from the South-Eastern European region and Israel who reviewed the existing evidence and guidelines for the treatment of PwT2D. Herein, the experts emphasised the timely use of insulin, preferably second-generation basal insulin (BI) analogues and intensification using basal-plus therapy, as the most-potent glucose-lowering treatment choice in the real-world clinical setting. Despite an increase in the use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs), the experts urged timely insulin initiation for inadequate glycaemic control in PwT2D. Furthermore, the combination of BI and GLP-1 RA addressing both fasting plasma glucose and post-prandial excursions as a free- or fixed-ratio combination was identified to reduce treatment complexity and burden. To minimise discontinuation and improve adherence, the experts reiterated quality, regular interactions and discussions between HCPs and PwT2D/carers for their involvement in the diabetes management decision-making process. Clinicians and HCPs should consider the opinions of the experts in accordance with the most recent recommendations for diabetes management.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
; Kempler, Peter 2 ; Guja, Cristian 3 ; Eldor, Roy 4 ; Haluzik, Martin 5 ; Klupa, Tomasz 6 ; Papanas, Nikolaos 7 ; Stoian, Anca Pantea 3 ; Mankovsky, Boris 8 1 Semmelweis University, Department of Internal Medicine and Oncology, Faculty of Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821); Semmelweis University, Department of Public Health, Faculty of Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821); University College London, UCL Brain Sciences, London, UK (GRID:grid.83440.3b) (ISNI:0000 0001 2190 1201)
2 Semmelweis University, Department of Internal Medicine and Oncology, Faculty of Medicine, Budapest, Hungary (GRID:grid.11804.3c) (ISNI:0000 0001 0942 9821)
3 Carol Davila University of Medicine and Pharmacy, Department of Diabetes, Nutrition and Metabolic Disease, Bucharest, Romania (GRID:grid.8194.4) (ISNI:0000 0000 9828 7548)
4 Tel Aviv Sourasky Medical Center, Diabetes Unit, Institute of Endocrinology, Metabolism and Hypertension, Tel-Aviv, Israel (GRID:grid.413449.f) (ISNI:0000 0001 0518 6922); Tel-Aviv University, The Faculty of Medicine, Tel-Aviv, Israel (GRID:grid.12136.37) (ISNI:0000 0004 1937 0546)
5 Institute for Clinical and Experimental Medicine, Diabetes Centre, Prague, Czech Republic (GRID:grid.418930.7) (ISNI:0000 0001 2299 1368)
6 Jagiellonian University Medical College, Center for Advanced Technologies in Diabetes & Department of Metabolic Diseases, Kraków, Poland (GRID:grid.5522.0) (ISNI:0000 0001 2337 4740)
7 Democritus University of Thrace, Second Department of Internal Medicine, Diabetes Centre, Diabetic Foot Clinic, Alexandroupolis, Greece (GRID:grid.12284.3d) (ISNI:0000 0001 2170 8022)
8 National Healthcare University of Ukraine, Department of Diabetology, Kiev, Ukraine (GRID:grid.415616.1) (ISNI:0000 0004 0399 7926)





